https://www.selleckchem.com/pr....oducts/mk-8353-sch90
sue factor pathway inhibitor in molecular markers and fibrinolytic markers can be used as indicators of platelet transfusion time and efficiency in patients with MDS. To explore the expression of clec2 in patients with myelodysplastic syndrome (MDS) and to analyze its correlation with TPO. The expression of plasma clec2 in 47 patients with MDS and 20 normal controls was detected by ELISA, and the correlation between the clinical characteristics of MDS patients and clec2 expression was analyzed. Meanwhile, the expression level
Like
Comment
Share
